Ambrus J L, Courey N G, Browne B J, Mink I B, Moore R H, Ambrus C M
Am J Obstet Gynecol. 1977 May 15;128(2):161-6. doi: 10.1016/0002-9378(77)90680-9.
Changes in the blood coagulation system were studied in three groups of 20 patients each. The first group received 0.5 mg. of norethindrone daily, plus 0.06 mg. of ethinyl estradiol on alternate days from cycle Day 5 through 25. The second group, all of whom had been fitted with an intrauterine contraceptive device (IUD), received no hormonal treatment and served as a control group. The third group received 0.5 mg. of norethindrone daily, combined with 0.045 mg. of ethinyl estradiol given on alternate days from cycle Day 5 through 25. Blood samples were drawn prior to the initiation of the study and after three months of treatment. Tests of the following parameters of the blood coagulation system were performed: direct platelet count; platelet adhesiveness; prothrombin time; thrombin time; fibrinogen; factor II assay; activity of factors V, VII, VIII, IX, and X; antithrombin III; and fibrin/fibrinogen degradation products. For a number of these factors, both fresh and frozen blood samples were examined. It was concluded that the two treatment regimens, with the use of alternate-day estrogen administration over a three-month period, had no clinically significant effect on the blood coagulation system.
对三组各20名患者的血液凝固系统变化进行了研究。第一组患者每天服用0.5毫克炔诺酮，从月经周期第5天至25天每隔一天加服0.06毫克炔雌醇。第二组患者均已放置宫内节育器（IUD），未接受激素治疗，作为对照组。第三组患者每天服用0.5毫克炔诺酮，从月经周期第5天至25天每隔一天加服0.045毫克炔雌醇。在研究开始前和治疗三个月后采集血样。对血液凝固系统的以下参数进行了检测：直接血小板计数；血小板黏附性；凝血酶原时间；凝血酶时间；纤维蛋白原；因子II测定；因子V、VII、VIII、IX和X的活性；抗凝血酶III；以及纤维蛋白/纤维蛋白原降解产物。对于其中一些因子，对新鲜和冷冻血样均进行了检测。得出的结论是，这两种治疗方案，即在三个月期间每隔一天服用雌激素，对血液凝固系统没有临床显著影响。
